While nabiximols is the only cannabis product approved and pharmacovigilance-monitored for neuropathic pain, the wide variety of other cannabis preparations used for pain lack adequate safety data.
People using cannabis for nerve pain, healthcare providers prescribing medical cannabis, regulators evaluating cannabis product safety
Only one cannabis product (nabiximols) is approved and safety-monitored for neuropathic pain
What the researchers found
Only nabiximols (a balanced CBD/THC product) is approved by regulatory authorities for neuropathic pain and included in pharmacovigilance systems. The many other cannabis preparations widely used for chronic nerve pain are unmonitored, creating insufficient knowledge of their safety profiles.
Why it matters
Millions of people use various cannabis preparations for chronic nerve pain, but without systematic safety monitoring, the true risk-benefit profile of most products remains unknown.
The numbers in context
Nabiximols contains similar percentages of CBD and THC; approved in many European countries and Canada for neuropathic pain and MS-related spasticity
How the study worked
Review of published clinical studies reporting adverse reactions from cannabis use for neuropathic pain relief.
What this study cannot tell us
Safety data limited to published clinical studies, which may not capture all real-world adverse reactions. Heterogeneous cannabis products make direct comparisons difficult.
How to read the evidence
Review of clinical study data with focus on adverse reactions from cannabis pain treatments
When this study was published
Published in 2021. The landscape of available cannabis products for pain continues to expand.
The bigger picture
The gap between the single approved cannabis pain product and the dozens of unregulated products people actually use highlights a broader regulatory challenge as medical cannabis use expands globally.
Questions still open
- Should cannabis preparations for pain be subject to the same pharmacovigilance requirements as approved medications? How do adverse effect profiles differ between various cannabis formulations used for pain?
Common questions
Is medical cannabis safe for nerve pain?
What is nabiximols?
Read the original research
Safety of Medical Cannabis in Neuropathic Chronic Pain Management.
Molecules (Basel, Switzerland), 26(20)
Citation
Bennici, Alessandra; Mannucci, Carmen; Calapai, Fabrizio; Cardia, Luigi; Ammendolia, Ilaria; Gangemi, Sebastiano; Calapai, Gioacchino; Griscti Soler, Daniel. (2021). Safety of Medical Cannabis in Neuropathic Chronic Pain Management.. Molecules (Basel, Switzerland), 26(20). https://doi.org/10.3390/molecules26206257
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk